Compare IDYA & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | CSTM |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | France |
| Employees | N/A | 11500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2019 | 2012 |
| Metric | IDYA | CSTM |
|---|---|---|
| Price | $31.03 | $21.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $51.54 | $33.52 |
| AVG Volume (30 Days) | 986.4K | ★ 1.6M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 405.26 |
| EPS | N/A | ★ 3.31 |
| Revenue | $218,710,000.00 | ★ $8,449,000,000.00 |
| Revenue This Year | N/A | $28.19 |
| Revenue Next Year | $216.42 | N/A |
| P/E Ratio | ★ N/A | $6.86 |
| Revenue Growth | ★ 3024.43 | 15.19 |
| 52 Week Low | $26.81 | $14.62 |
| 52 Week High | $42.68 | $36.99 |
| Indicator | IDYA | CSTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 33.66 |
| Support Level | $29.74 | N/A |
| Resistance Level | $35.44 | $27.18 |
| Average True Range (ATR) | 1.53 | 1.10 |
| MACD | -0.21 | -0.26 |
| Stochastic Oscillator | 4.75 | 20.70 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.